CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 750 enrolled
Drug / intervention
SER120 (750 ng/day) +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01357356
NCT01357356Phase 3Completed
CompareCT.gov

A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicenter Study to Investigate the Efficacy and Safety of SER120 Nasal Spray Formulations in Patients With Nocturia

Serenity Pharmaceuticals, Inc.·interventional·Posted May 20, 2011·Updated Oct 8, 2020

In Brief

A Phase 3 clinical trial evaluating SER120 (750 ng/day), SER120 (1000 ng/day), and 2 other interventions for Nocturia. Completed, enrolled 750 participants across 1 site.

Detailed Summary

The purpose of this study is to investigate the efficacy and safety of SER120 nasal spray formulations in patients with nocturia for a total duration of 14 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNocturia
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMay 20, 2011
Enrollment StartMay 1, 2011
Primary CompletionOct 1, 2012
Study CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 15.1 years ago

Interventions

SER120 (750 ng/day)drug

SER120 (1000 ng/day)drug

SER120 (1000 ng/day)

SER120 (1500 ng/day)drug

Placebodrug